BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...CFO from SVP of finance; and Marianne Mancini to COO from SVP of clinical operations. Destiny Pharma plc...
...will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem Inc. Viking Therapeutics Inc. Destiny Pharma plc...
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

...two biotechs completed IPOs on AIM last year, dermatology company SkinBioTherapeutics plc and anti-infectives play Destiny Pharma...
...TPEx:6497), Singapore BeiGene Ltd. (NASDAQ:BGNE), Beijing, China China Food and Drug Administration (CFDA), Beijing, China Destiny Pharma...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...AB (SSE:SENZA) 9/19/17 $11.3 $26.3 $83.9 219% AbClon Inc. (KOSDAQ:174900) 9/18/17 $6.1 $61.2 $138.6 127% Destiny Pharma...
BioCentury | Sep 8, 2017
Financial News

Destiny raises L15.3M in placing

...On Sept. 4, anti-infectives play Destiny Pharma Ltd. (LSE:DEST) raised £15.3 million ($19.8 million) through the sale...
...157p in a placing to new and existing investors. Destiny Pharma Ltd. (LSE:DEST), Falmer, U.K. Elizabeth S. Eaton Destiny Pharma...
BioCentury | Sep 12, 2016
Clinical News

Exeporfinium chloride: Phase I data

...placebo. The trial was sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Destiny Pharma...
BioCentury | Nov 23, 2015
Clinical News

XF-73 regulatory update

...methicillin-resistant S. aureus (MRSA). The dicationic porphyrin is in Phase I/IIa development for the indication. Destiny Pharma...
BioCentury | Aug 11, 2014
Financial News

Destiny Pharma completes venture financing

Destiny Pharma Ltd. , Falmer, U.K. Business: Infectious Date completed: 2014-08-04 Type: Venture financing Raised: L2.8 million ($4.7 million) Investors: Angel CoFund; and other investors Note: The company said it raised over L2.8 million ($4.7 million)...
BioCentury | Apr 2, 2012
Clinical News

XF-73: Phase I started

...50 subjects. NIH's National Institute of Allergy and Infectious Diseases (NIAID) is funding the trial. Destiny Pharma...
Items per page:
1 - 8 of 8
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...CFO from SVP of finance; and Marianne Mancini to COO from SVP of clinical operations. Destiny Pharma plc...
...will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem Inc. Viking Therapeutics Inc. Destiny Pharma plc...
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

...two biotechs completed IPOs on AIM last year, dermatology company SkinBioTherapeutics plc and anti-infectives play Destiny Pharma...
...TPEx:6497), Singapore BeiGene Ltd. (NASDAQ:BGNE), Beijing, China China Food and Drug Administration (CFDA), Beijing, China Destiny Pharma...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...AB (SSE:SENZA) 9/19/17 $11.3 $26.3 $83.9 219% AbClon Inc. (KOSDAQ:174900) 9/18/17 $6.1 $61.2 $138.6 127% Destiny Pharma...
BioCentury | Sep 8, 2017
Financial News

Destiny raises L15.3M in placing

...On Sept. 4, anti-infectives play Destiny Pharma Ltd. (LSE:DEST) raised £15.3 million ($19.8 million) through the sale...
...157p in a placing to new and existing investors. Destiny Pharma Ltd. (LSE:DEST), Falmer, U.K. Elizabeth S. Eaton Destiny Pharma...
BioCentury | Sep 12, 2016
Clinical News

Exeporfinium chloride: Phase I data

...placebo. The trial was sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Destiny Pharma...
BioCentury | Nov 23, 2015
Clinical News

XF-73 regulatory update

...methicillin-resistant S. aureus (MRSA). The dicationic porphyrin is in Phase I/IIa development for the indication. Destiny Pharma...
BioCentury | Aug 11, 2014
Financial News

Destiny Pharma completes venture financing

Destiny Pharma Ltd. , Falmer, U.K. Business: Infectious Date completed: 2014-08-04 Type: Venture financing Raised: L2.8 million ($4.7 million) Investors: Angel CoFund; and other investors Note: The company said it raised over L2.8 million ($4.7 million)...
BioCentury | Apr 2, 2012
Clinical News

XF-73: Phase I started

...50 subjects. NIH's National Institute of Allergy and Infectious Diseases (NIAID) is funding the trial. Destiny Pharma...
Items per page:
1 - 8 of 8